SpectrumDNA Net Margin
The Net Profit Margin of SpectrumDNA (SPXA) as of Jul 14, 2026 is -1,392.99 %.
Get this data via API
Financial Data API
Net Margin
-1,392.99 %
Last updated:
Net Profit Margin of SpectrumDNA is 2026 -1,392.99 % . Net Profit Margin of SpectrumDNA was 2025 - . It decreases by % lower compared to the previous year.
SpectrumDNA's net margin stands at -1,393.0%, up from -3,394.4% several years earlier.
Access this data via the Eulerpool API
SpectrumDNA Stock analysis
What does SpectrumDNA do? SpectrumDNA Inc is a company specializing in the development and marketing of genetic tests and analyses. Founded in 2013, the company is based in Austin, Texas and is one of the leading companies in the field of DNA analysis.
The history of SpectrumDNA goes back to its founders, Dr. Jamie Teumer and Dr. João Silveira. Both bring years of experience in genetics and molecular biology and have worked on numerous research projects. Their goal was to make genetics accessible to everyone and improve healthcare. With this drive, they founded SpectrumDNA and began to put their idea into action.
SpectrumDNA's business model is based on the creation of genetic tests and analyses that allow people to know their personal risk for certain diseases or conditions and take targeted preventive measures. SpectrumDNA works closely with doctors and other healthcare experts to interpret and implement the results and recommendations of the tests.
SpectrumDNA offers a variety of genetic tests and analyses targeting various areas of health and well-being. These include tests for identifying genetic risk factors for cancer, cardiovascular diseases, Alzheimer's, and Parkinson's, as well as tests for predicting behavioral traits and physical characteristics such as lactose intolerance or hair color.
The company also has its own research and development department that constantly works on advancing and improving test methods and technologies. This ensures that customers at SpectrumDNA always receive the latest and most accurate information.
SpectrumDNA has also specialized in developing products based on the genetic profiles of its customers. These include personalized supplements tailored to the individual needs of the customer, as well as personalized training plans based on the customer's genetic traits.
Recently, SpectrumDNA has also focused its attention on the application of genetics in the beauty industry. The company has developed a procedure that allows the analysis of skin quality and aging process based on the customer's genetic profile. Based on this analysis, a personalized skincare program is created that is tailored to the individual needs and goals of the customer.
Overall, SpectrumDNA is a leading company in the field of DNA analysis and specializes in personalized healthcare services. Through close collaboration with doctors and other healthcare providers, as well as constant advancement and improvement of its technologies and products, SpectrumDNA enables its customers to improve their health and well-being in a personalized and effective way. SpectrumDNA is one of the most popular companies on Eulerpool.
Frequently Asked Questions about SpectrumDNA stock
Net Profit Margin of SpectrumDNA is -1,392.99 % in 2026.
Access this data via the Eulerpool API
Margins — SpectrumDNA
All Key Metrics — SpectrumDNA
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth